Top Markets
Coin of the day
CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASI
Κατάταξη σε μετοχές #36784
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the... CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.
Τιμή μετοχής
$0.15
Τελευταίος συγχρονισμός: 2026-04-13
Κεφαλαιοποίηση
$2.33M
Αλλαγή (1 ημέρα)
3.88%
Αλλαγή (1 έτος)
-93.70%
Χώρα
CN
Εμπόριο CASI Pharmaceuticals, Inc. (CASI)

Κατηγορία

Ιστορικό τιμής μετοχής για την CASI Pharmaceuticals, Inc. (CASI)
Υψηλότερη τιμή κλεισίματος: $0.14 στις 2026-04-01

Χαμηλότερη τιμή κλεισίματος: $1.67K στις 1996-06-01
Ιστορικό τιμής μετοχής της CASI Pharmaceuticals, Inc. από 1996 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2026 (TTM) 32.52%
2025 -72.44%
2024 -53.46%
2023 283.37%
2022 -79.05%
2021 -68.42%
2020 -16.54%
2019 -24.32%
2018 30.06%
2017 155.84%
2016 26.21%
2015 -27.36%
2014 -14.44%
2013 12.11%
2012 11.08%
2011 -77.05%
2010 -43.19%
2009 302.44%
2008 -82.88%
2007 -24.57%
2006 -17.29%
2005 -25.64%
2004 -20.23%
2003 227.92%
2002 -87.78%
2001 -56.55%
2000 -23.06%
1999 11.82%
1998 101.68%
1997 -19.22%
1996 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE